Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics

The safety, pharmacokinetics, and antitumor activity of the multikinase inhibitor regorafenib in Japanese patients was assessed in this multicenter, single-arm, phase I trial. Fifteen patients with treatment-refractory advanced solid tumors received regorafenib 160 mg once daily for the first 3 week...

Descripción completa

Detalles Bibliográficos
Autores principales: Sunakawa, Yu, Furuse, Junji, Okusaka, Takuji, Ikeda, Masafumi, Nagashima, Fumio, Ueno, Hideki, Mitsunaga, Shuichi, Hashizume, Kensei, Ito, Yuichiro, Sasaki, Yasutsuna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913857/
https://www.ncbi.nlm.nih.gov/pubmed/23553067
http://dx.doi.org/10.1007/s10637-013-9953-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913857/
https://www.ncbi.nlm.nih.gov/pubmed/23553067
http://dx.doi.org/10.1007/s10637-013-9953-8

Ejemplares similares